Antibodies against oxidized low density lipoproteins in pregnant women

Physiological Research

Volumn 51, Issue 4, 2002, Pages 355-361

  Fialova L ^a   Mikulikova L ^a   Malbohan, I ^a   Benesova O ^b   Stipek S ^a   Zima, T ^a   Zwinger, A ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR THE CARE OF MOTHER AND CHILD   (Czech Republic)

Author keywords

Alpha 1 fetoprotein; Antibodies against oxidized low density lipoproteins; Human chorionic gonadotrophin; Pregnancy; Trophoblast specific beta 1 glycoprotein

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; IMMUNODIFFUSION; MATERNAL BLOOD; MATERNAL HYPERTENSION; OXIDATIVE STRESS; PATHOGENESIS; PREECLAMPSIA; PREGNANCY; SECOND TRIMESTER PREGNANCY;

ADULT; AUTOANTIBODIES; FEMALE; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; LIPOPROTEINS, LDL; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND;

EID: 0036407683     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Adcock EW, Teasdale F, August CS: Human chorionic gonadotropin - Its possible role in maternal lymphocyte suppression. Science 181: 845-847, 1973.
2. Amengua L., Atsumi T, Khamashta MA, Tinahones F, Hughes GR: Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 36: 964-968, 1997.
3. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL: Pre-eclampsia and serum antibodies to oxidized low density lipoprotein. Lancet 343: 645-646, 1994.
4. Brown H: Antiphospholipid antibodies and recurrent pregnancy loss. Clin Obstet Gynecol 34: 17-26, 1991.
5. Festa A, Kopp HP, Schernthaner G, Menzel EJ: Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 41: 350-356, 1998.
6. Fialová L. Malbohan I, Mikulíková, L, Hájek Z: Biochemical screening of congenital developmental abnormalities using determination of fetoplacental antigens. Acta Univ Carol Med 39: 3-8, 1993.
7. Fialová, L, Mikulíková, L, Matouš-Malbohan I, Benešová, O, Zwinger A: Prevalence of various antiphospholipid antibodies in pregnant women. Physiol Res 49: 299-305, 2000.
8. Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli S, Branch DW, Palinski W, Witztum JL: Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 98: 815-825, 1996.
9. Hubel CA: Dyslipidemia, iron, and oxidative stress in preeclampsia: Assessment of maternal and feto-placental interactions. Semin Reprod Endocrinol 16: 75-92, 1998.
10. Kaplan M, Aviram M: Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 37: 777-787, 1999.
11. Kurki T, Ailus K, Palosuo T, Ylikorkala O: Antibodies to oxidized low-density lipoprotein, cardiolipin, and phosphatidylserine fail to predict the risk of preeclampsia. Hypertens Pregnancy 15: 251-256, 1996.
12. Little R.E, Gladen BC: Levels of lipid peroxides in uncomplicated pregnancy: A review of the literature. Reprod Toxicol 13: 347-352, 1999.
13. Lopes-Virella MF, Griffith RL, Shunk KA, Virella GT: Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb 11: 1356-1367, 1991.
14. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker RW, Forrest KY: Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 90: 165-172, 1999.
15. Malbohan I, Fialová, L, Mikulíková, L, Hájek Z: Prenatal biochemical diagnostics of inborn developmental defects. Sborn Lék 95: 277-283, 1994.
16. Mironova M, Virella G, Lopes-Virella MF: Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol 16: 222-229, 1996.
17. Morris JM, Gopaul NK, Endresen MJ, Knight M, Linton EA, Dhir S, Anggard EE, Redman CW: Circulating markers of oxidative stress are raised in normal pregnancy and pre-eclampsia. Br J Obstet Gynaecol 105: 1195-1199, 1998.
18. Murgita RA: The immunosuppressive role of alpha-fetoprotein during pregnancy. Scand J Immunol 5: 1003-1014, 1976.
19. Palinski W, Witztum JL: Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Inten Med 247: 371-380, 2000.
20. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86: 1372-1376,1989.
21. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL: Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis 10: 325-335, 1990.
22. Roberts JM:: Preeclampsia: What we know and what we do not know. Semin Perinatol 24: 24-28, 2000.
23. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL: Antibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339: 883-887, 1992.
24. Sinisalo J, Paronen J, Mattila KJ, Syrjälä M, Alfthan G, Palosuo T, Nieminen MS, Vaarala O: Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis 149: 403-411, 2000.
25. Steinerová, A, Racek J, Stožický F, Zima T, Fialová, L, Lapin A: Antibodies against oxidized LDL - Theory and clinical use. Physiol Res 50: 131-141, 2001.
26. Štípek S: Volné radikály - Dobří sluhové a zlí páni, In: Antioxidanty a Volné Radikály ve Zdraví a v Nemoci. S ŠTíPEK et al. (eds), Grada Publishing, Praha, 2000, pp. 41-108.
27. Tatzber F, Esterbauer H: Autoantibodies to oxidized low density lipoprotein, In: Free Radicals, Lipoprotein Oxidation and Atherosclerosis IX. G Bellomo, C Rice-Evans (eds), Richelieu Press, London, 1995, pp 245-260
28. Tulppala M, Ailus K, Palosuo T, Ylikorkala O: Antibodies to oxidized low density lipoprotein and to cardiolipin in nonpregnant and pregnant women with a history of habitual abortion. Fertil Steril 64: 947-950, 1995.
29. Uotila J, Solakivi T, Jaakkola O, Tuimala R, Lehtimäki T: Antibodies against copper-oxidised and malondialdehyde-modified low density lipoproteins in pre-eclampsia pregnancies. Br J Obstet Gynaecol 105: 1113-1117, 1998.
30. Vaarala O: Antibodies to oxidised LDL. Lupus 9: 202-205, 2000.
31. Vaarala O, Puurunen M, Lukka M, Alfthan G, Leirisalo Repo M, Aho K, Palosuo T: Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidised low-density lipoprotein. Clin Exp Immunol 104: 269-274, 1996.
32. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo Repo M, Aho K, Palosuo T: Crossreaction between antibodies to oxidised lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341: 923-925, 1993.
33. Wu R, De Faire U, Lemne C, Witztum JL, Frostegard J: Autoantibodies to ox-LDL are decreased in individuals with borderline hypertension. Hypertension 33: 53-59, 1999.
34. Zeman M, Žák A, Fialová L, Mikulíková L, Tvrzická E, Buchtíková M: Antibodies anti oxidized LDL - Clinical relations. Klin Biochem Metab 8: 177-182, 2000.
35. Žák A: Oxidační stress a kardiovaskulární onemocněni, In: Antioxidanty a Volné Radikály ve Zdraví a v Nemoci. S Štípek et al. (eds), Grada Publishing, Praha. 2000, pp. 117-144.